At a glance
ClinicalIndex Comparison Record- ✓Histologic diagnosis of classical Hodgkin's lymphoma
- ✓Primary refractory or relapsed disease proven by biopsy
- ✓Relapse or refractory disease following 1 line of multi-agent chemotherapy (not including pembro-GVD)
- ✓Eligible for HDT/ASCT
- ✕More than 1 prior treatment line for Hodgkin Lymphoma
- ✕Known pregnancy or breast-feeding
- ✕Medical illness unrelated to Hodgkin's Lymphoma making participation inappropriate
- ✕Prior radiotherapy within 2 weeks of study start
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Second-line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
In Brief
A Phase 2 clinical trial evaluating pembrolizumab, gemcitabine, and 3 other interventions for Hodgkin Lymphoma and Relapsed or Refractory Hodgkin Lymphoma. Currently recruiting, targeting 257 participants across 10 sites.
Signals
Detailed Summary
The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.
Study Details
Timeline
Interventions
Age 10-17: 2mg/kg (cap at 200mg), Age ≥ 18: 200 mg (flat) ,Day 1 of each 3 week cycle IV infusion 2-4 cycles (pre-ASCT)
1000mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
20mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
15mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
Stem cell mobilization and collection will be performed as per standard MSKCC guidelines after 2-4 cycles of pembrolizumab-GVD.